Gastrodin reduces the accumulation of phosphorylated tau (p-tau) and amyloid-beta (Aβ), inhibits lead-induced brain inflammation, and increases the expression of NR2A and BDNF. This evidence concerns the gene MAPT and brain inflammatory disease.